The MAKE Biomarker Discovery for Enhancing anTidepressant Treatment Effect and Response (MAKE BETTER) Study: Design and Methodology
Article information
Psychiatry Investig. 2019;16(10):791-792
1Department of Psychiatry, Chonnam National University Medical School, Gwangju, Republic of Korea
2Mental Health Clinic, Chonnam National University Hwasun Hospital, Hwasun, Republic of Korea
3Department of Biomedical Science, Chonnam National University Medical School, and Clinical Trial Center, Chonnam National University Hospital, Gwangju, Republic of Korea
4Department of Laboratory Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea
Psychiatry Investig 2018;15(5):538-545
https://doi.org/10.30773/pi.2017.10.2
In the original publication, the schedule of follow-up assessment was incorrect. The description in the study design and recruitment of the Method section has been changed as follows: Eligible patients with depressive disorders who agreed to participate in the MAKE BETTER study were approached for follow-up assessments at 1, 2, 3, 6 and 9 weeks; 3 months; and every 3 months thereafter up to 2 years to determine the short- and long-term treatment outcomes and clinical course of their depressive disorder. Accordingly, the has been changed as follows. The authors sincerely regret these missing errors.
Schedule of assessment for MAKE BETTER study
Article information Continued
Copyright © 2019 Korean Neuropsychiatric Association
Table 2.
Schedule of assessment for MAKE BETTER study
|
Base-line |
1 weeks |
2 weeks |
3 weeks |
6 weeks |
9 weeks |
3 Month |
6 Month |
9 Month |
12 Month |
15 Month |
18 Month |
21 Month |
24 Month |
Clinical assessment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Socio-demographic characteristics |
√ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Psychological characteristics |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Personality |
√ |
|
|
|
|
|
√ |
|
|
√ |
|
|
|
|
|
|
Social support |
√ |
|
|
|
|
|
√ |
|
|
√ |
|
|
|
√ |
|
|
Stress-related status |
√ |
|
|
|
|
|
√ |
|
|
√ |
|
|
|
√ |
|
|
Outcomes of depression |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depressive symptom |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
|
|
Functional disability |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
|
|
Suicidality |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
|
|
Quality of life |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
Biological assessment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Blood biomarker |
√ |
|
|
|
|
|
|
|
|
√ |
|
|
|
|
|
Salivary cortisol (cortisol study only) |
√ |
|
√ |
|
√ |
|
√ |
√ |
|
|
|
|
|
|
|
Electrocardiography |
√ |
|
|
|
|
|
|
|
|
√ |
|
|
|
|
|
Resting BP, body mass index |
√ |
|
√ |
|
√ |
|
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
Treatment related assessment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Antidepressants, dosage, duration |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
|
Adverse events |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
|
Withdrawal |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |
√ |